thursday februari 3 1994 part ii depart health human servic food drug administr 21 cfr part 351 vagin drug product counter human use withdraw advanc notic propos rulemak feder regist vol 59 23 thursday februari 3 1994 propos rule usdept depart health human servic usdept usbureau food drug administr usbureau 21 cfr part 351 rindock docket 82n0291 rindock rindock rin 0905aa06 rindock vagin drug product counter human use withdraw advanc notic propos rulemak agenc agenc food drug administr hh agenc action action notic withdraw advanc notic propos rulemak action summari summari food drug administr fda issu notic withdraw advanc notic propos rulemak octob 13 1983 48 fr 46694 would establish condit counter otc vagin drug product gener recogn safe effect misbrand fda issu notic withdraw consid report recommend advisori review panel otc contracept vagin drug product vagin panel public comment advanc notic propos rulemak base recommend action taken part agenc determin recommend label indic relat cosmet claim drug claim addit recommend label indic ingredi use minor irrit itch sore uniqu vagin area alreadi consid otc drug rulemak e g antifung antimicrobi extern analges therefor ingredi indic consid rulemak appropri summari inform contact william e gilbertson center drug evalu research hfd810 food drug administr 5600 fisher lane rockvil md 20857 3015945000 supplem supplementari inform feder regist octob 13 1983 48 fr 46694 fda publish 330 10 6 21 cfr 330 10 6 advanc notic propos rulemak establish monograph otc vagin drug product togeth recommend vagin panel advisori review panel respons evalu data activ ingredi drug class interest person invit submit comment januari 11 1984 repli comment respons comment file initi comment period could submit march 19 1984 accord 330 10 10 data inform consid vagin panel put public display docket manag branch hfa305 food drug administr rm 123 12420 parklawn dr rockvil md 20857 delet small amount trade secret inform notic fda state first time posit establish monograph otc vagin drug product base vagin panel conclus recommend otc vagin drug product comment receiv agenc independ evalu vagin panel report preambl advanc notic propos rulemak otc vagin drug product 48 fr 46694 46695 agenc express concern 1 abil woman recogn natur caus symptom vagin itch irrit sore order determin kind drug product select treat condit 2 whether 1 2 week self medic otc drug product may pose unaccept delay seek profession attent symptom itch irrit sore due n gonorrhoea trichomona candida organ erad topic therapi nonantimicrobi otc drug product time final agenc decis made regard vagin panel recommend state concern agenc invit specif comment issu respons advanc notic propos rulemak four drug manufactur two trade associ nine consum four medic associ two pharmaceut associ three surgeon gener one poison control center three consum group two commun health associ three practic medic group submit comment copi comment receiv public display docket manag branch address otc volum cite throughout document refer submiss made interest person pursuant call data notic publish feder regist may 16 1973 38 fr 12840 addit inform come agenc attent sinc public advanc notic propos rulemak volum public display docket manag branch docket number 82n0291 agenc tent conclus comment gener comment 1 one comment contend otc drug monograph interpret oppos substant regul comment refer statement issu submit earlier otc drug rulemak proceed agenc address issu paragraph 85 91 preambl procedur classif otc drug product publish feder regist may 11 1972 37 fr 9464 9471 9472 paragraph 3 preambl tent final monograph otc antacid drug product publish feder regist novemb 12 1973 38 fr 31260 fda reaffirm conclus state document court decis confirm agenc author issu substant regul rulemak see e g nation nutrit food associ v weinberg 512 f 2d 688 696698 2d cir 1975 nation associ pharmaceut manufactur v fda 487 f supp 412 n 1980 aff 637 f 2d 887 2d cir 1981 2 one comment disagre vagin panel statement activ ingredi present therapeut concentr product drug even product claim produc effect result action therapeut effect ingredi 48 fr 46694 46701 comment argu drug statu product determin intend use inclus certain ingredi presenc certain ingredi product offer sole cosmet make product drug comment state fda polici concern drug versu cosmet statu state mani document includ procedur regul govern otc drug review 37 fr 9464 9475 vagin panel properli appli polici comment ad justif appli differ principl rulemak vagin drug product comment request term drug product use throughout regul wherev product specif identifi emphas differ cosmet drug product e g vagin douch drug product feder food drug cosmet act act provid statutori definit differenti drug cosmet drug defin part articl intend use diagnosi cure mitig treatment prevent diseas intend affect structur function bodi see 21 u c 321 g 1 b c cosmet hand defin articl intend appli human bodi part thereof cleans beautifi promot attract alter appear see 21 u c 321 1 therefor agenc agre comment intend use product primari determin factor whether product drug cosmet intend use may infer product label promot materi advertis relev factor see e g nation nutrit food ass n v mathew 557 f 2d 325 334 2d cir 1977 type amount ingredi present product even product make explicit drug claim must consid determin regulatori statu exampl mere presenc pharmacolog activ ingredi could make product drug even absenc explicit drug claim case intend use would impli known recogn drug effect ingredi e g fluorid dentifric agenc believ necessari use term drug product throughout otc drug monograph distinguish drug cosmet product label final monograph appli product fall within statutori definit drug appli cosmet product howev product intend drug cosmet use e g cleans treat diseas condit must conform requir applic final monograph otc drug product well bear appropri label cosmet use conform section 602 act 21 u c 362 provis part 701 740 21 cfr part 701 740 3 respons agenc specif request comment appropri otc drug product treat symptom itch irrit sore around vagina 48 fr 46694 46695 sever comment state treat symptom otc drug product appropri ration therapi women readili recogn symptom benefit deriv use drug far outweigh risk associ otc avail number comment state valid medic basi conclud suggest fda preambl advanc notic propos rulemak otc topic antifung drug product 47 fr 12480 march 23 1982 seriou health hazard could result self treat symptom extern feminin itch comment contend likelihood mask seriou gynecolog disord gonorrhea trichomoniasi mask seriou condit diabet highli unlik provid label product advis consum consult physician symptom worsen persist longer 1 week support content seriou complic delay proper medic diagnosi like occur symptom extern vagin itch treat otc drug product one comment cite safe market experi otc hydrocortison product label indic includ extern genit feminin itch comment state none possibl problem project e mask seriou diseas inabl self diagnos presum side effect drug materi sinc market otc hydrocortison began 1979 sever comment also argu extern vagin itch irrit necessarili caus infect often caus irrit cloth sensit cosmet inappropri hygien extern factor contrast sever comment state women never self treat symptom vagin itch irrit sore capabl self diagnosi e specif determin appropri drug product use base variou vagin symptom alway evalu physician comment ad self treatment could unreason delay proper diagnosi could even complic agenc note product submit vagin panel intend intravagin use except vagin contracept use otc vagin product e g douch suppositori part limit cosmet purpos e g cleans deodor mechan flush thu agenc conclud except indic relat minor itch irrit sore recommend vagin monograph indic list vagin panel report 48 fr 46694 46729 cosmet natur outsid scope otc drug review e g astring remov vagin discharg remov vagin secret mild deterg action indic vagin product refer product transitori cleans effect rather claim therapeut effect see drug cosmet discuss comment 2 therefor except astring claim see comment 13 agenc consid indic outsid scope otc drug review agenc object continu avail vagin product bear label claim relat cleans cosmet purpos believ cosmet product label use therapeut purpos except advic supervis physician result withdraw notic manufactur may need relabel reformul product futur howev reformul relabel necessari cost minim reformul relabel requir event appropri rulemak agenc believ consum access otc drug product provid temporari relief vagin itch irrit agenc recogn safe market experi hydrocortison avail otc sinc 1979 indic includ use itchi anal genit area provid support seriou complic delay proper medic diagnosi like occur symptom vagin itch treat otc drug product therefor base avail data inform agenc believ relief vagin symptom itch irrit accept label claim certain otc drug product state product submit vagin panel intend intravagin use concern aros self diagnosi select appropri drug product self treatment intravagin disord fertil matern health drug advisori committe committe meet held june 14 15 1990 discuss propos vagin fungicid sold otc treatment yeast candida infect although mechan initi self diagnosi consid committe believ consum could safe adequ recogn treat subsequ intravagin yeast infect initi diagnosi made physician recommend vagin antifung drug product whose safeti well establish made avail otc appropri label ref 1 base committe recommend avail data agenc determin certain otc drug product intravagin use treat yeast infect relief minor irrit itch sore safe use otc howev recommend agenc believ antifung drug product ingredi otc intravagin use appropri women previous diagnos physician condit drug product intend therefor abl subsequ recogn symptom condit agenc intend discuss propos label specif ingredi otc intravagin use amend final monograph otc antifung drug product futur issu feder regist number ingredi otc drug product could use around vagina reliev symptom itch irrit sore use ingredi specif uniqu vagin area e could use topic reliev symptom elsewher bodi exampl antifung antiprurit skin protect astring potenti reliev symptom occur extern around vagina well part bodi note howev certain drug product class e g antifung may capabl reliev itch irrit mean kill caus itch e g yeast fungu product would expect routin effect treat itch due caus e g poison ivi eczema insect bite etc also otc drug rulemak agenc includ appropri variou condit ingredi consid gener recogn safe effect otc use one monograph see exampl discuss hydrocortison use psoriasi 51 fr 27346 27360 discuss menstrual claim intern analges 53 fr 46204 46209 therefor ingredi consid safe effect use reliev condit around vagina agenc believ appropri includ vagin claim applic otc drug monograph rather separ monograph ingredi claim relat vagin use see exampl extern feminin itch claim hydrocortison product includ tent final monograph otc extern analges drug product 48 fr 5852 5868 therefor base discuss agenc withdraw advanc notic propos rulemak otc vagin drug product indic intent creat new subpart b propos part 351 withdraw reflect agenc intent regard languag previous publish potenti codif part 351 negat reject advisori panel report specif vagin claim variou pharmacolog class ingredi consid appropri monograph issu rais comment may significantli affect otc drug rulemak agenc believ use respond issu document issu agenc respons also discuss appropri otc drug rulemak interest person may time submit comment applic rulemak refer 1 summari minut fertil matern health drug advisori committe date june 1415 1990 otc vol 11btfm 4 sever comment support recommend advisori review panel otc antimicrobi ii drug product antimicrobi ii panel propos prescript otc switch certain topic antifung drug treat extern feminin itch associ yeast infect 47 fr 12480 comment stress candid yeast infect vagina extrem common recurr women recogn reason certainti yeast infect especi one agenc awar three otc advisori review panel charg review product could use around vagina conclud vagin infect could self diagnos self treat panel conclus consist fda polici infect gener self diagnos consum self treat otc drug product except gener polici otc use topic antifung treat athlet foot jock itch ringworm antimicrobi ii panel review topic antifung drug product fda determin infect common recurr amen self diagnosi treatment addit antimicrobi ii panel recommend haloprogin miconazol nystatin switch prescript otc statu extern feminin itch associ yeast infect antimicrobi ii panel recommend ingredi treatment infect believ otc avail ingredi would benefici provid rapid symptomat relief itch issu consum diagnosi recurr infect appropri physician diagnosi initi infect discuss panel consider issu antimicrobi ii panel also recommend haloprogin miconazol nystatin avail otc treatment superfici skin infect caus yeast candida 47 fr 12480 12565 howev agenc conclud tent final monograph otc antifung drug product 54 fr 51136 51140 antifung ingredi label otc use treatment cutan candidiasi howev agenc state cutan candidiasi claim effect antifung ingredi could appropri includ profession label state comment 3 light recommend committe agenc reevalu posit avail antifung drug product otc treatment vagin yeast candida infect antifung ingredi clotrimazol miconazol nitrat specif concentr approv otc intravagin use specif indic new drug applic ref 1 2 refer 1 label nda 18052 gyne lotrimin vagin cream otc vol 11btfm docket 82n0291 docket manag branch 2 label nda 17450 monistat 7 vagin cream otc vol 11btfm docket 82n0291 docket manag branch 5 one comment disagre vagin panel recommend ingredi classifi categori ii use otc vagin drug product remov automat vagin cosmet product 48 fr 46694 46710 comment state action unwarr safeti cosmet ingredi assur manufactur consid scientif analys done otc advisori panel fda also addit publish unpublish data may review panel comment also contend specif use ingredi cosmet may differ use drug product agenc note vagin panel made recommend discuss categori ii combin vagin drug product vagin panel recommend agenc categori ii ingredi caus combin product place categori ii safeti reason remov product regardless whether intend use drug cosmet concern protect consum unsaf ingredi share vagin panel concern agenc agre comment automat remov categori ii drug ingredi cosmet product warrant factor need consid exampl ingredi may safe one concentr use drug may accept use lower concentr cosmet product howev agenc look care ingredi present cosmet product ingredi found unsaf use otc drug product fda prepar take appropri regulatori action prevent use ingredi cosmet product potenti health hazard known exist continu use see 21 cfr part 700_subpart b 6 one comment state vagin panel may inappropri suggest need effect test vagin drug product final formul 48 fr 46694 46724 46725 comment stress otc drug review intend activ ingredi review test necessari final formul product discuss test guidelin vagin douch product vagin panel simpli state requir effect test douch make cosmet claim e g cleans howev vagin panel recommend effect test requir ingredi vagin douch make drug claim e g reliev irrit discuss comment 3 agenc withdraw advanc notic propos rulemak otc vagin drug product refer consider specif claim ingredi use around vagina appropri otc drug rulemak necessari final formul test also discuss rulemak e g ingredi use vagin antisept drug product b comment activ ingredi 7 two comment object vagin panel conclus data insuffici prove safeti quaternari ammonium compound e benzalkonium chlorid benzethonium chlorid methylbenzethonium chlorid vagin use 48 fr 46694 46717 comment state although vagin panel concern base publish literatur report use compound associ infect caus pseudomona scientif sound use report conclud safeti problem exist comment mention vagin panel fail state report result contamin solut employ laboratori hospit set steril medic devic use urinari cardiac catheter cystoscop relat invas procedur procedur usual conduct patient whose normal bodi defens compromis pseudomona infect occur primarili debilit patient pseudomona caus vulvovagin comment state scientif inappropri cite report extrapol conclud use quaternari ammonium compound vagin drug product present health hazard normal individu comment cite sever refer ref 1 7 show vagin panel concern respect vagin contamin pseudomona presenc quaternari ammonium compound support weight scientif data comment ad extens toxicolog studi compound publish ref 8 comment request agenc affirm safeti quaternari ammonium compound classifi categori use reliev minor irrit vagina anoth comment state quaternari ammonium compound histor includ vagin product preserv ingredi allow continu use purpos agenc agre comment reason report cite vagin panel pseudomona infect adequ conclud use quaternari ammonium compound otc vagin drug product may present health hazard normal individu agenc object continu use quaternari ammonium compound preserv otc drug cosmet product provid product manufactur accord establish procedur assur adequaci preserv system microbi limit product respect use quaternari ammonium compound activ ingredi otc vagin drug product reliev symptom itch irrit sore vagin panel state unawar data demonstr effect use 48 fr 46694 46718 comment includ new data agenc unawar data explain comment 3 agenc decid consid specif vagin claim variou ingredi appropri rulemak quaternari ammonium compound includ categori ingredi tent final monograph otc first aid antisept drug product publish feder regist juli 22 1991 56 fr 33644 comment new data receiv regard specif vagin use quaternari ammonium compound consid agenc rulemak otc topic antimicrobi drug product refer 1 forkner jr c e pseudomona aeruginosa infect modern medic monograph vol 22 edit wright r h orr gruen stratton new york pp 7173 1960 2 gardner h l r h kaufman nonvener bacteri vulvovaginitid benign diseas vulva vagina c v mosbi co st loui p 212 1969 3 charl major problem obstetr gynecolog w saunder co pp 45 1980 4 pidieu c vulva major problem dermatolog vol 5 edit rook w b saunder co philadelphia p 99 1979 5 monif g r f infecti diseas obstetr gynecolog 2d edit harper row hagerstown md pp 524525 1982 6 mead p b w gump antibiot therapi obstetr gynecolog clinic obstetr gynecolog edit h j osofski g schaefer harper row hagerstown md pp 109129 1976 7 gardner et al long term multicent trial ta ro cap new spermicid product contracept 20 489495 1979 8 finnegan j k j b dienna toxic quaternari soap sanitari chemic februari 1954 8 one comment support vagin panel categori classif potassium sorbat 48 fr 46694 46704 disagre agenc conclus potassium sorbat new drug market drug materi extent materi time unit state 48 fr 46694 46695 comment state product contain potassium sorbat market 2 year ingredi gener recogn safe effect treatment minor vagin itch irrit includ monograph ingredi comment contend potassium sorbat safe recogn vagin panel lack report major side effect advers reaction complaint 14 million unit product contain ingredi sold 2 year market discontinu comment argu potassium sorbat effect recogn vagin panel base two adequ well control clinic studi 48 fr 46694 46704 comment ad ingredi histor use physician treatment vagin itch irrit profession use constitut use materi time materi extent comment also argu potassium sorbat safer povidon iodin vagin panel recommend categori ingredi use comment conclud potassium sorbat new drug histor use market histori place categori monograph ingredi preambl vagin panel report 48 fr 46694 46695 agenc state opinion follow agenc awar market drug product contain potassium sorbat activ ingredi prior adopt panel report although least one product enter marketplac sinc time potassium sorbat market drug materi extent materi time unit state agenc consid ingredi new drug within mean section 201 p feder food drug cosmet act 21 u c 321 p may market fda approv new drug applic nda use agenc time chang posit potassium sorbat treatment minor vagin itch irrit howev issu agenc interpret regard market materi extent materi time threshold criteria inclus ingredi otc drug review rais number rulemak citizen petit ref 1 2 file request agenc chang longstand posit threshold criteria especi regard permit foreign market satisfi materi time extent criteria agenc intend address materi time extent issu consolid respons futur issu feder regist refer 1 comment cp2 cp3 cp4 docket 78n0038 docket manag branch 2 comment cp1 docket 92p0309 docket manag branch 9 one comment request categori approv povidon iodin activ ingredi relief minor irrit vagina extend includ vagin suppositori well douch dosag form comment state absorpt potenti suppositori dosag form greater vagin douch basi make distinct suppositori douch dosag form respect effect respons comment compar rel safeti potassium sorbat povidon iodin see comment 8 one comment contend safeti effect question rais comment respect povidon iodin superfici erron disregard fact comment state 1 000 publish studi 30 year experi demonstr safeti effect povidon iodin confirm categori statu vagin use douch povidon iodin variou formul vagin use e douch gel origin review fda drug efficaci studi implement desi desi panel conclud povidon iodin effect douch e cleans purpos povidon iodin could offer partial temporari relief itch odor infect present douch formul defer consider otc drug review feder regist octob 13 1983 48 fr 46694 46705 vagin panel review povidon iodin douch product 0 15 3 percent place categori relief minor irrit vagina vagin panel review povidon iodin suppositori dosag form data dosag form submit howev vagin panel consid suppositori dosag form claim relat relief minor irrit reduct number pathogen microorgan state claim must substanti test 48 fr 46694 46702 safeti effect povidon iodin relief itch minor irrit around vagina discuss agenc rulemak otc topic antimicrobi drug product futur issu feder regist see also discuss comment 17 regard profession label claim c comment label 10 one comment object vagin panel recommend otc drug label compon perfum includ product comment explain fragranc flavor often made dozen ingredi list individu would practic imposs furthermor composit perfum signific trade secret comment point issu consid reject congress fda sever occas past decad conclud reason whatsoev chang previou decis section 502 e act 21 u c 352 e specifi requir label activ inact ingredi drug product need includ requir otc drug monograph howev agenc note although section 502 e act requir complet identif inact ingredi label otc drug requir disclosur certain ingredi whether includ activ inact compon drug product although fda requir inclus inact ingredi otc drug product label agenc urg manufactur list inact ingredi voluntarili recommend vagin panel inform enabl consum known allergi intoler certain ingredi select product increas confid safe use vagin panel made recommend fda nonprescript drug manufactur associ ndma formerli proprietari associ trade associ repres otc drug manufactur reportedli market 90 95 percent otc drug product sold unit state implement program member compani voluntarili list inact ingredi label otc drug product guidelin establish ndma ref 1 although guidelin specifi list ingredi contain fragranc perfum product provid inact ingredi flavor fragranc list flavor fragranc henc consum known allergi intoler inact ingredi flavor fragranc perfum would gener awar inclus certain otc drug product agenc commend voluntari effort urg otc drug manufactur label product voluntarili accord ndma guidelin refer 1 proprietari associ adopt voluntari disclosur inact ingredi news releas proprietari associ washington may 14 1984 copi includ otc vol 11btfm docket 82n0291 docket manag branch 11 sever comment argu fda cannot legal matter polici prescrib exclus list term statement ident indic use otc drug product must drawn prohibit altern otc label terminolog truth mislead intellig consum describ indic two comment argu restrict unconstitut restrict commerci speech exce fda author one comment state exclus polici warrant matter sound public polici recommend fda follow guidelin label polici instead exclus one one comment object advanc notic propos rulemak restrict limit statement ident regul 201 61 21 cfr 201 61 comment urg agenc allow manufactur altern way describ statement ident allow 201 61 feder regist may 1 1986 51 fr 16258 agenc publish final rule chang label polici state indic use otc drug product 330 1 c 2 21 cfr 330 1 c 2 label label otc drug product requir contain promin conspicu locat either 1 specif word indic use establish otc drug monograph may appear within box area design approv use 2 word describ indic use meet statutori prohibit fals mislead label shall neither appear within box area design approv use 3 approv monograph languag indic may appear within box area design approv use plu altern languag describ indic use fals mislead shall appear elsewher label otc drug label requir monograph regul e g statement ident warn direct must appear specif word establish otc drug monograph regul exact languag establish identifi quotat mark e g 201 63 330 1 g 12 one comment state fda exclus polici drug label polici applic cosmet claim appear label product cosmet drug agenc agre comment label restrict otc drug monograph appli product fall within statutori definit drug cosmet product distinct drug cosmet discuss comment 3 final otc drug monograph cover drug use activ ingredi list therein concentr rang limit statement ident indic warn direct establish ingredi monograph appli use ingredi product intend sole cosmet howev product intend drug cosmet use must conform requir applic final monograph addit indic allow otc drug product bear claim vagin use product may also bear appropri label cosmet use conform section 602 act provis part 701 740 accord final rule agenc exclus polici 51 fr 16258 may 1 1986 cosmet claim may appear within box area design approv use discuss 51 fr 16258 16264 paragraph 14 cosmet claim may appear elsewher label box manufactur choos label altern provid 330 1 c 2 c 2 iii label cosmet drug product 13 one comment agre vagin panel conclus term cleans produc sooth refresh effect deodor use definit vagin douch vagin suppositori cosmet claim 48 fr 46694 46701 comment urg agenc accept vagin panel recommend addit claim anoth comment also consid claim produc astring effect cosmet claim comment argu claim make vagin product drug legal inappropri includ definit product propos 351 103 monograph remov definit section anywher els appear document agenc agre cosmet claim includ otc drug rulemak therefor cosmet claim cleans sooth refresh deodor includ otc drug monograph agenc believ howev astring either drug claim cosmet claim depend intend use label product exampl astring product intend label relief minor vagin irrit reduct local edema would consid drug astring product intend label refresh effect would consid cosmet product make claim would drug cosmet thu agenc consid intend use determin whether cosmet drug see also comment 3 14 one comment state vagin panel categor cosmet claim categori ii drug claim inappropri cosmet claim within jurisdict otc drug review comment contend follow claim inappropri classifi categori ii drug claim vagin panel 48 fr 46694 46710 claim realli cosmet claim effect cleans effect deodor clean thoroughli destroy odor continu vagin cleanli cleans thoroughli douch remov contracept jelli cream chang water cleans solut complet feminin hygien person hygien hypoallergen feminin hygien intim cleanli prevent disagre odor effect germ killer routin feminin hygien complet refresh comment also contend vagin panel place follow product qualiti claim categori ii claim belong rulemak drug claim fortifi tripl strength scientif balanc formula intim understood chang water cleans solut natur safe ingredi formula like natur environ bodi ph 3 5 effect liquid nonacid intend women want enjoy extra confid meet peopl vagin douch function cover odor unlik spray deodor offer less protect complet feminin dainti clinic test dainti feminin gentl safe delic membran contain mildest ingredi complet compat normal vagin environ buffer control normal vagin ph state vagin panel provid reason recommend comment request refer claim delet next stage rulemak although anoth stage rulemak comment concern regard label term relev vagin claim otc drug product subject otc drug monograph therefor agenc believ pertin address comment concern otc drug review establish condit otc drug gener recogn safe effect misbrand two princip condit examin review allow ingredi allow label fda determin practical_in term time resourc considerations_to set standard label found otc drug product accordingli otc drug monograph regul label relat signific way safe effect use cover product lay person otc drug monograph establish allow label follow item product statement ident name activ ingredi indic use direct use warn unsaf use side effect advers reaction claim concern mechan drug action agenc agre comment claim list either sole cosmet claim relat signific way safe effect use otc vagin drug product therefor outsid scope otc drug review although term consid outsid scope review use label otc drug product evalu agenc product product basi provis section 502 act relat label fals mislead moreov term outsid scope review even though truth mislead may appear portion label requir monograph may detract requir inform howev term outsid scope monograph may includ elsewher label provid fals mislead addit explain comment 2 label restrict final monograph appli product fall within statutori definit drug cosmet product howev product intend drug cosmet use must conform requir applic final monograph also section 602 act regul part 701 740 15 one comment contend use adject vagin modifi douch statement ident 351 152 unnecessari superflu common languag usag word douch becom synonym vagin use comment ad agenc codifi class product douch prepar 21 cfr 369 20 comment request statement ident allow synonym vagin douch feminin douch dispos douch douch comment argu term vagin douch may sensit certain advertis media request synonym plu accompani label would clearli defin product intend vagin use agenc recogn sensit use word vagin take consider develop label appropri otc drug monograph see e g label develop hydrocortison tent final monograph otc extern analges drug product 48 fr 5852 5868 16 one comment object vagin panel recommend propos 351 152 b two statement keep drug reach children prevent pregnanc appear princip display panel otc vagin drug product comment argu includ statement princip display panel contrari label requir otc drug regul effect statement gener requir display warn section next direct use comment argu vagin douch product shown less safe differ otc drug product extent would necessit inclus separ warn statement comment request vagin panel recommend propos 351 152 b delet statement includ recommend label warn propos 351 154 agenc agre comment special placement warn statement princip display panel unwarr vagin panel recommend statement keep drug reach children appear princip display panel attract color appear mani vagin drug product may encourag children open consum content 48 fr 46694 46708 agenc unawar evid otc vagin drug product attract like open consum children otc drug product therefor agenc determin need special placement gener warn statement label otc vagin drug product exist regul 330 1 g 21 cfr 330 1 g alreadi requir otc drug contain warn keep drug reach children need includ warn individu otc drug monograph howev vagin panel concern commonli held misconcept peopl douch prevent pregnanc 48 fr 46694 46708 agenc encourag manufactur voluntarili place warn prevent pregnanc label vagin douch product agenc discuss vagin drug product label regard prevent pregnanc sexual transmit diseas part rulemak otc antifung drug product futur issu feder regist 17 one comment urg delet vagin panel recommend profession label statement propos 351 180 b 3 read use povidon iodin douch may caus transient rise serum protein bound iodin comment argu view vagin panel conclus transient rise serum protein bound iodin level observ individu affect safeti drug shown clinic signific respect thyroid function 48 fr 46694 46705 statement unwarr comment ad inclus statement profession label mislead direct unwarr emphasi essenti meaningless event comment also state agenc decid delet statement statement amend read follow affect safeti use povidon iodin douch may caus transient rise serum protein bound iodin individu transient elev return normal within 7 30 day evid clinic signific respect thyroid function comment contend revis statement would present full clinic signific rise serum protein bound iodin accord vagin panel state find discuss comment 9 agenc intend consid povidon iodin vagin use rulemak otc topic antimicrobi drug product futur issu feder regist tent final monograph povidon iodin categori ingredi antifung 54 fr 51136 decemb 12 1989 first aid antisept 56 fr 33644 juli 22 1991 statement regard transient rise protein bound iodin associ use povidon iodin includ profession label profession label associ vagin use povidon iodin consid part antimicrobi rulemak consid comment combin 18 one comment request vagin panel recommend list permit combin propos 351 120 amend provid combin one categori ingredi two three four variou pharmacolog class comment state adequ preced otc drug review combin categori ingredi one pharmacolog class categori ingredi anoth pharmacolog class without necess elabor test combin explain comment 3 agenc withdraw advanc notic propos rulemak otc vagin drug product refer consider specif vagin claim appropri otc drug rulemak likewis combin ingredi vagin claim consid respect rulemak consid 19 agenc recogn vagin panel recommend profession label indic sever ingredi review see propos 351 180 48 fr 46694 46729 combin product contain ingredi dioctyl sodium sulfosuccin docus sodium sodium lauryl sulfat vagin panel recommend indic treatment trichomona vaginali combin product contain ingredi calcium propion sodium propion vagin panel recommend indic treatment candida albican ingredi povidon iodin vagin panel recommend indic clinic effect program treatment vagin moniliasi vaginal vagin nonspecif vagin preambl vagin panel report 48 fr 46694 46695 agenc disagre vagin panel recommend regard calcium propion sodium propion base previou decis made agenc respect ingredi desi program agenc place profession label indic recommend vagin panel calcium propion sodium propion categori ii agenc reaffirm categor document agenc also state preambl vagin panel report otc market ingredi relief minor vagin irrit could take place time studi reli upon panel review agenc found inadequ desi agenc invit comment data would support panel recommend safeti effect calcium propion sodium propion ingredi otc vagin drug product comment new data submit therefor agenc reaffirm conclus ingredi singli combin may market otc drug product claim vagin use recommend profession label claim docus sodium sodium lauryl sulfat panel reli upon one publish studi ref 1 support recommend agenc evalu studi find insuffici determin safeti effect ingredi treatment trichomona vaginali studi satisfi criteria adequ well control clinic studi includ control group addit design determin effect ingredi treat trichomona rather determin effect ph remov secret vagina therefor ingredi singli combin may market otc drug product claim includ profession label claim vagin use regard activ ingredi povidon iodin panel 48 fr 46694 46705 state adequ data support claim effect vagin yeast candidiasi moniliasi vaginal vagin nonspecif vagin use treatment regimen consist dilut douch full strength 10 percent povidon iodin product vagin panel 48 fr 46694 46700 believ claim therapeut benefit treatment specif vagin infect must restrict profession label e g treatment trichomoniasi moniliasi label full strength 10 percent product includ monograph howev agenc sinc conclud recur vagin yeast candida infect safe treat otc agenc current review data vagin panel consid well subsequ petit file support variou vagin claim formul povidon iodin ref 4 agenc discuss use povidon iodin treatment vagin yeast candida infect futur feder regist public part rulemak otc antifung drug product two clinic studi cite data submiss otc drug review support vagin claim ref 2 3 agenc review two clinic studi conclud insuffici demonstr povidon iodin effect treatment vagin neither studi satisfi criteria adequ well control studi control group includ therefor insuffici demonstr effect povidon iodin treatment vagin refer 1 fischer r r deterg alkalin douch pacif medicin surgeri 73 209212 1965 2 shook clinic studi povidon iodin regimen resist vagin current therapeut research 5 256263 1963 3 ratzan j j monili trichomon vagin topic treatment povidon iodin prepar california medicin 110 2427 1969 4 comment cp docket 82n0291 docket manag branch ii agenc conclus otc vagin drug product fda consid comment relev data inform avail time determin specif claim ingredi use around vagina includ appropri otc drug rulemak accordingli advanc notic propos rulemak publish feder regist octob 13 1983 48 fr 46694 would ad new subpart b vagin drug product counter human use propos part 351 vagin contracept vagin drug product counter human use propos 21 cfr part 351 herebi withdrawn effect februari 3 1994 discuss claim cosmet claim consid otc drug rulemak ingredi drug claim relat use around vagina consid appropri otc drug rulemak agenc identifi follow rulemak appropri consider ingredi claim vagin drug use 1 antifung drug product docket 80n0476 2 extern analges drug product docket 78n0301 3 skin protect drug product docket 78n0021 4 topic antimicrobi drug product docket 75n0183 agenc emphas withdraw advanc notic propos rulemak drug product withdraw way denigr scientif content report negat excel work vagin panel long effort produc fda believ inform vagin panel report provid valuabl guidanc agenc respect ingredi vagin claim otc drug rulemak withdraw advanc notic propos rulemak affect current market statu product consid vagin panel report withdraw notic issu author sec 201 501 502 503 505 510 701 feder food drug cosmet act 21 u c 321 351 352 353 355 360 371 agenc determin 21 cfr 25 24 c 6 action type individu cumul signific effect human environ therefor neither environment assess environment impact statement requir date decemb 10 1993 supplem signer michael r taylor signer signjob deputi commission polici signjob frfile fr doc 942263 file 2294 8 45 frfile bill bill code 416001f bill